A new treatment option for patients with HCC
eMediNexus, 11 November 2018
remove_red_eye 732 Views
#Gastroenterology #Internal Medicine #Pathology and Lab Medicine
remove_red_eye 732 Views
#Gastroenterology #Internal Medicine #Pathology and Lab Medicine
The FDA has expanded the indications for pembrolizumab (Keytruda) to include advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib (Nexavar)
To continue reading this article
Sign in with Medtalks
Sign in with Facebook
Continue reading your article with a eMediNexus account.
Free Membership!
